Sputnik V vaccine

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:accessories gptkb:various_countries
gptkbp:approves gptkb:Russia
fast-tracked in some countries
gptkbp:average_temperature -18° C
gptkbp:clinical_trial over 40,000
multiple countries
Phase III
February 2021
completed Phase I, II, III
gptkbp:collaborations with global health organizations
gptkbp:developed_by Gamaleya Research Institute
gptkbp:disease_resistance varies by region
gptkbp:distribution over 70 countries
gptkbp:dosage_form gptkb:battle
2
91.6%
gptkbp:economic_impact considerable
gptkbp:has_variants studied
https://www.w3.org/2000/01/rdf-schema#label Sputnik V vaccine
gptkbp:is_effective_against gptkb:The_Lancet
gptkbp:is_vulnerable_to gptkb:virus
gptkb:Ability
gptkb:significant
ongoing
affordable
logistical issues
strong immune response
limited in some regions
continuing for new variants
reduction in COVID-19 cases
against severe disease
adverse event monitoring ongoing
repurposed adenoviral vector
gptkbp:manager intramuscular
gptkbp:manufacturer Russian Direct Investment Fund
gptkbp:market ongoing
gptkbp:moral discussed in public forums
gptkbp:operating_hours 3 weeks apart
gptkbp:origin gptkb:Sputnik_satellite
gptkbp:partnerships international organizations
various pharmaceutical companies
gptkbp:public_awareness implemented in various countries
gptkbp:public_perception mixed
gptkbp:receives_funding_from government and private sources
gptkbp:regulatory_compliance multiple countries
faced in some regions
gptkbp:release_date August 2020
gptkbp:safety_features generally well tolerated
gptkbp:side_effect fatigue
headache
fever
injection site pain
gptkbp:status Emergency Use Listing
gptkbp:storage up to 6 months at -18° C
gptkbp:targets gptkb:COVID-19
gptkbp:type viral vector vaccine
gptkbp:bfsParent gptkb:COVID-19_pandemic_in_Iran
gptkbp:bfsLayer 6